Women of high parity comprised an identifiable subgroup that was less likely to attend screening in the setting studied.
The overall prevalence of HIV in pregnant women who agreed to screening in the study clinics during the period of the trial was approximately 1.5%.
There was no population-based mammography screening in the study area.
All 31 peptides were selected at any screening in the study.
The predicted uptake to screening in the study is high compared to actual uptake rates in CRC.
Table 3 summarizes the knowledge and attitudes about cervical screening in the study population.> -wrap-foot> N = Number of respondents.
Few municipalities invited only 50- to 59-year-old women to biannual mammography screening in the study period 1992 2003.
They cite screening in the control group but fail to consider continued voluntary screening in the study group after invitations had ceased.
Study population is large and can be considered well representative of women aged between 25 and 60 years who participate in screening in the study areas.
For two of the trials, the incidence extended only 6 years beyond the end of screening in the study group, so the overdiagnosis estimates in the review are also likely to be overestimates.
If this bias were present in our study, the differences in the incidence of AVN may be explained by systematically different levels of AVN screening in the study groups.
